Erik Ewing, MD
Family Medicine · Hixson, TNNPI 1316326960
Payments from drug & device makers
Across 458 payments — averaging $17.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$940
- AbbVie$815
- Amgen$524
- Pfizer$455
- Lilly USA, LLC$342
- plus $3K from 32 others
What the payments were for
- Food & beverage$7,70497%
- Education$2223%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 78 | $1,530 |
| AstraZeneca | 50 | $940 |
| AbbVie(2 entities) | 66 | $815 |
| Amgen | 36 | $524 |
| Pfizer | 27 | $455 |
| Lilly USA, LLC | 23 | $342 |
| Bayer | 17 | $330 |
| Astellas Pharma US Inc | 10 | $328 |
| Johnson & Johnson | 15 | $321 |
| Amarin Pharma, Inc. | 15 | $272 |
| Merck | 20 | $237 |
| GSK | 14 | $237 |
| Boehringer Ingelheim | 11 | $186 |
| Sanofi-aventis U.S. LLC | 9 | $154 |
| Centinel Spine, LLC | 1 | $119 |
| Esperion Therapeutics, Inc. | 6 | $103 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $102 |
| Sumitomo Pharma America, Inc. | 5 | $100 |
| Novartis | 5 | $100 |
| Kowa Pharmaceuticals America, Inc. | 7 | $95 |
| Abbott | 5 | $94 |
| Axsome Therapeutics, Inc. | 4 | $72 |
| Redhill Biopharma Inc. | 4 | $62 |
| Gilead | 4 | $53 |
| E.r. Squibb & Sons, L.L.C. | 3 | $50 |
| Xeris Pharmaceuticals, Inc. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $31 |
| Boston Scientific | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Agios Pharmaceuticals, Inc. | 1 | $23 |
| Seqirus USA Inc | 1 | $22 |
| Nevro Corp. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $16 |
| Antares Pharma, Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
| Irhythm Technologies, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,925 in reported general payments places this provider in the 85th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 129 | $179,292 |
| OzempicSemaglutide | 87 | $157,998 |
| MounjaroTirzepatide | 104 | $134,324 |
| TrulicityDulaglutide | 58 | $100,353 |
| FarxigaDapagliflozin Propanediol | 73 | $74,400 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 49 | $58,942 |
| MyrbetriqMirabegron | 40 | $46,423 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $30,952 |
| RybelsusSemaglutide | 20 | $29,444 |
| DescovyEmtricitabine/Tenofov Alafenam | 13 | $27,481 |
| XareltoRivaroxaban | 32 | $26,344 |
| JanuviaSitagliptin Phosphate | 25 | $24,282 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 15 | $22,685 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 47 | $14,868 |
| LinzessLinaclotide | 14 | $14,293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $342 | $234,677162 claims |
| Novo NordiskOzempic, Rybelsus | $1,530 | $187,442107 claims |
| PfizerEliquis, Abrysvo | $455 | $184,019144 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $940 | $133,342122 claims |
| Astellas Pharma US IncMyrbetriq | $328 | $46,42340 claims |
| GSKTrelegy Ellipta, Arexvy | $237 | $45,82076 claims |
| GileadDescovy | $53 | $27,48113 claims |
| Johnson & JohnsonXarelto | $321 | $26,34432 claims |
| MerckJanuvia | $237 | $24,28225 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $154 | $22,68515 claims |
| AbbVieLinzess | $815 | $14,29314 claims |
| NovartisEntresto | $100 | $10,95413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Hixson
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.